NewsALIMENTARY PHARMACOLOGY & THERAPEUTICSWednesday, February 18, 2026 · February 18, 2026
Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.
WHY IT MATTERS
Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
Nearly 40% of patients with primary biliary cholangitis (PBC) have an incomplete response to first-line ursodeoxycholic acid (UDCA) therapy. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, is an effective second-line treatment for PBC. Compared to the recently...
Related conditions
Related news
Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.…